Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ESMO
ESMO
Esmo 2020 – More encouraging signs for checkpoint bispecifics
EP Vantage
Tue, 09/22/20 - 10:56 am
ESMO
bispecifics
Macrogenics
Akeso
mesothelioma
AK104
MGD019
Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients
BioSpace
Mon, 09/21/20 - 11:40 pm
Mirati Therapeutics
sitravantinib
ESMO
urothelial cancer
#ESMO20: Bristol Myers marks Opdivo's second adjuvant win — eyeing a standard of care gap
Endpoints
Mon, 09/21/20 - 11:27 pm
Bristol-Myers Squibb
ESMO
Opdivo
esophageal cancer
ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with fresh survival stats
Fierce Pharma
Mon, 09/21/20 - 10:57 am
Libtayo
ESMO
Regeneron
Sanofi
non-small cell lung cancer
Amgen publishes, presents data on therapy with ‘undruggable’ target
MedCity News
Mon, 09/21/20 - 10:33 am
Amgen
sotorasib
ESMO
AMG 510
non-small cell lung cancer
Esmo 2020 – some backing for Beigene’s unusual combo approach
EP Vantage
Mon, 09/21/20 - 10:26 am
ESMO
BeiGene
urothelial cancer
ESMO: Roche’s Akt inhibitor scores slight win over J&J’s Zytiga
Fierce Biotech
Sun, 09/20/20 - 08:02 pm
Roche
prostate cancer
ESMO
JNJ
Ipatasertib
Zytiga
ESMO: Merck and AstraZeneca's 5-Year Lynparza Data in Ovarian Cancer and More
BioSpace
Sun, 09/20/20 - 08:00 pm
ESMO
Merck
AstraZeneca
clinical tirals
Lynparza
ovarian cancer
ESMO: Roche's mixed results put Tecentriq's triple-negative breast cancer use into question
Fierce Pharma
Sun, 09/20/20 - 07:57 pm
ESMO
Roche
Tecentriq
triple negative breast cancer
Merck
Keytruda
ESMO: Lilly's Verzenio pressures Pfizer with practice-changing win in early breast cancer
Fierce Pharma
Sun, 09/20/20 - 07:54 pm
Ibrance
Pfizer
Eli Lilly
Verzenio
breast cancer
ESMO
ESMO: Pfizer, Merck KGaA's Bavencio comes up short against placebo in risky head and neck cancer trial
Fierce Pharma
Sat, 09/19/20 - 09:20 pm
ESMO
Pfizer
Merck KGaA
Bavencio
head and neck cancer
clinical trials
ESMO: Novartis parses long-awaited survival data for breast cancer blockbuster hopeful Piqray
Fierce Pharma
Sat, 09/19/20 - 09:12 pm
ESMO
Novartis
breast cancer
Piqray
Faslodex
AstraZeneca
ESMO: Merck's Keytruda-chemo combo shows survival 'trend,' but can't top chemo in bladder cancer
Fierce Pharma
Sat, 09/19/20 - 09:11 pm
Merck
ESMO
bladder cancer
metastatic bladder cancer
Keytruda
#ESMO20: AstraZeneca burnishes Tagrisso's adjuvant NSCLC profile with 'unprecedented' reduction in brain mets. Can they win over skeptics?
Endpoints
Sat, 09/19/20 - 09:05 pm
AstraZeneca
Tagrisso
non-small cell lung cancer
ESMO
Seattle Genetics stays step ahead of rivals with bladder cancer data
BioPharma Dive
Sat, 09/19/20 - 09:04 pm
Seattle Genetics
Astellas
Padcev
bladder cancer
clinical trials
ESMO
ESMO: Alkermes' major I-O hope sees progress across early cancer tests
Fierce Biotech
Fri, 09/18/20 - 11:09 am
Alkermes
immuno-oncology
ESMO
ALKS 4230
Keytruda
Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer
Seeking Alpha
Fri, 09/18/20 - 10:45 am
ESMO
Mirati Therapeutics
clinical trials
sitravantinib
Opdivo
urothelial cancer
Esmo 2020 preview – late-breaking immunotherapy
EP Vantage
Mon, 09/14/20 - 10:53 am
ESMO
immunotherapy
Big Pharma
Merck
Bristol-Meyers Squibb
cancer
Immunomedics
Roche
ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysis
Fierce Pharma
Tue, 12/17/19 - 09:29 pm
ESMO
Roche
Tecentriq
non-small cell lung cancer
Here's Why Seattle Genetics Climbed 17.6% in September
Motley Fool
Mon, 10/7/19 - 11:25 pm
Seattle Genetics
ESMO
clinical trials
tucatinib
colorectal cancer
enfortumab vedotin
urothelial cancer
Pages
« first
‹ previous
1
2
3
4
5
6
next ›
last »